BSE: 530199 | NSE: THEMISMED | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Themis Medicare Ltd is a average quality company.
The key valuation ratios of Themis Medicare Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Themis Medicare Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 10% | 16.8% | 14.7% | 9.3% | -1.2% | 12.8% | 17% | 31.3% | 19.7% | 11.4% | - |
| Value Creation Index ⓘ | -0.3 | 0.2 | 0.1 | -0.3 | -1.1 | -0.1 | 0.2 | 1.2 | 0.4 | -0.2 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 167 | 203 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 382 | 386 |
| Sales YoY Gr. | - | 21.6% | 6.8% | -3.3% | -12.1% | 9.5% | 14.4% | 71.1% | -10.2% | 7.7% | - |
| Adj EPS ⓘ | 0.3 | 1.8 | 1.7 | 1 | -1.4 | 1.7 | 2.9 | 6.6 | 4.5 | 2.6 | 4 |
| YoY Gr. | - | 532.1% | -6.2% | -38% | -239.8% | NA | 65.7% | 130.5% | -32.1% | -42.6% | - |
| BVPS (₹) ⓘ | 5.8 | 7.6 | 15.4 | 16.9 | 15.6 | 17.3 | 20.2 | 26.4 | 30.6 | 32.7 | 35.3 |
| Adj Net Profit ⓘ | 2.3 | 15.1 | 15 | 9.4 | -13.3 | 15.8 | 26.2 | 60.5 | 41 | 23.6 | 37 |
| Cash Flow from Ops. ⓘ | 11 | 18.7 | -1.5 | 7.9 | 11 | 0.3 | 57 | 34.4 | 16.1 | 22 | - |
| Debt/CF from Ops. ⓘ | 10 | 5.1 | -54.6 | 10.2 | 7.5 | 299.2 | 1.5 | 2.3 | 5.7 | 4.4 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 9.6% | 15.7% | 18.3% | 7.7% | ||||
| Adj EPS ⓘ | 27.9% | NA | -3.5% | -42.6% | ||||
| BVPSⓘ | 21.3% | 16.1% | 17.5% | 6.9% | ||||
| Share Price | 33.8% | 61.1% | 45.7% | 80.3% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 4.8 | 26.6 | 14.6 | 6.3 | -8.9 | 10.4 | 15.2 | 28.2 | 15.6 | 8.1 | 11.7 |
| Op. Profit Mgn % ⓘ | 6.8 | 15.5 | 15.1 | 12.1 | 1.4 | 17.7 | 21.6 | 24.2 | 19 | 13.5 | 16.5 |
| Net Profit Mgn % ⓘ | 1.4 | 7.4 | 6.9 | 4.5 | -7.2 | 7.8 | 11.4 | 15.3 | 11.6 | 6.2 | 9.5 |
| Debt to Equity ⓘ | 2.2 | 1.5 | 0.6 | 0.5 | 0.6 | 0.6 | 0.5 | 0.3 | 0.3 | 0.3 | 0 |
| Working Cap Days ⓘ | 245 | 194 | 183 | 225 | 291 | 302 | 276 | 176 | 250 | 272 | 121 |
| Cash Conv. Cycle ⓘ | 45 | 46 | 76 | 116 | 171 | 181 | 166 | 95 | 144 | 168 | 61 |
Sales growth is growing at healthy rate in last 3 years 18.29%
Sales growth is good in last 4 quarters at 25.87%
Return on Equity has declined versus last 3 years average to 11.70%
Net Profit has been subdued in last 3 years -3.51%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 4 | 5.8 |
| TTM Sales (₹ Cr.) | 386 | 420 |
| BVPS (₹.) ⓘ | 35.3 | 44.8 |
| Reserves (₹ Cr.) ⓘ | 316 | 403 |
| P/BV ⓘ | 8.11 | 6.40 |
| PE ⓘ | 72.05 | 49.75 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 152.65 / 313.65 |
| All Time Low / High (₹) | 1.20 / 313.65 |
| Market Cap (₹ Cr.) | 2,636 |
| Equity (₹ Cr.) | 9.2 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 43 |
| Pledged * | 23.51 | 23.51 | 23.51 | 23.51 | 23.51 | 23.51 | 2.43 | 2.43 | 2.43 | 2.43 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 167 | 203 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 382 |
| Operating Expenses ⓘ | 156 | 171 | 184 | 184 | 182 | 166 | 181 | 299 | 287 | 330 |
| Manufacturing Costs | 30 | 42 | 41 | 36 | 32 | 35 | 33 | 52 | 49 | 55 |
| Material Costs | 65 | 62 | 56 | 58 | 59 | 52 | 67 | 131 | 101 | 115 |
| Employee Cost | 29 | 32 | 40 | 45 | 46 | 44 | 40 | 52 | 66 | 82 |
| Other Costs ⓘ | 32 | 35 | 48 | 46 | 45 | 34 | 41 | 64 | 71 | 77 |
| Operating Profit ⓘ | 11 | 31 | 32 | 25 | 3 | 36 | 50 | 96 | 67 | 52 |
| Operating Profit Margin (%) | 6.5% | 15.5% | 14.9% | 12.0% | 1.4% | 17.7% | 21.6% | 24.2% | 19.0% | 13.5% |
| Other Income ⓘ | 12 | 3 | 3 | 4 | 3 | 3 | 4 | 7 | 12 | 5 |
| Interest ⓘ | 14 | 12 | 12 | 12 | 12 | 13 | 13 | 9 | 10 | 9 |
| Depreciation ⓘ | 7 | 7 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 12 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 2 | 15 | 16 | 9 | -15 | 18 | 32 | 84 | 59 | 35 |
| Tax ⓘ | 0 | -1 | 2 | 0 | -2 | 2 | 6 | 22 | 16 | 10 |
| Profit After Tax | 2 | 15 | 15 | 9 | -13 | 16 | 27 | 62 | 43 | 25 |
| PAT Margin (%) | 1.2% | 7.4% | 6.8% | 4.4% | -6.9% | 7.9% | 11.5% | 15.6% | 12.2% | 6.5% |
| Adjusted EPS (₹) | 0.2 | 1.8 | 1.6 | 1.0 | -1.4 | 1.7 | 2.9 | 6.7 | 4.7 | 2.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 10% | 15% | 7% | 11% | 19% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 49 | 64 | 140 | 155 | 143 | 159 | 185 | 243 | 282 | 301 |
| Share Capital ⓘ | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves ⓘ | 40 | 56 | 130 | 146 | 134 | 150 | 176 | 234 | 273 | 292 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 97 | 82 | 66 | 75 | 76 | 88 | 79 | 67 | 77 | 74 |
| Long Term Debt | 44 | 30 | 12 | 11 | 9 | 12 | 22 | 24 | 28 | 27 |
| Short Term Debt | 54 | 52 | 53 | 64 | 67 | 77 | 57 | 43 | 49 | 47 |
| Trade Payables | 58 | 33 | 32 | 31 | 35 | 30 | 31 | 32 | 40 | 47 |
| Others Liabilities ⓘ | 20 | 41 | 36 | 26 | 39 | 45 | 43 | 56 | 67 | 77 |
| Total Liabilities ⓘ | 225 | 220 | 273 | 288 | 293 | 322 | 338 | 398 | 467 | 499 |
Fixed Assets | ||||||||||
| Gross Block | 151 | 156 | 131 | 141 | 146 | 147 | 172 | 192 | 221 | 239 |
| Accumulated Depreciation | 59 | 67 | 7 | 15 | 23 | 31 | 39 | 48 | 59 | 71 |
| Net Fixed Assetsⓘ | 92 | 89 | 124 | 126 | 123 | 116 | 133 | 144 | 162 | 168 |
| CWIP ⓘ | 3 | 5 | 9 | 2 | 2 | 8 | 2 | 3 | 3 | 3 |
| Investmentsⓘ | 11 | 11 | 12 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
| Inventories | 48 | 45 | 48 | 50 | 53 | 54 | 58 | 61 | 69 | 71 |
| Trade Receivables | 40 | 40 | 48 | 69 | 73 | 103 | 78 | 101 | 145 | 178 |
| Cash Equivalents | 6 | 8 | 9 | 7 | 3 | 5 | 25 | 26 | 19 | 19 |
| Others Assetsⓘ | 25 | 21 | 23 | 23 | 26 | 24 | 31 | 52 | 57 | 49 |
| Total Assets ⓘ | 225 | 220 | 273 | 288 | 293 | 322 | 338 | 398 | 467 | 499 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 11 | 19 | -2 | 8 | 11 | 0 | 57 | 34 | 16 | 22 |
| PBT ⓘ | 16 | 27 | 16 | 9 | -15 | 18 | 32 | 84 | 59 | 35 |
| Adjustment ⓘ | 6 | 6 | 17 | 17 | 19 | 18 | 17 | 11 | 14 | 17 |
| Changes in Working Capital ⓘ | 3 | -2 | -35 | -19 | 7 | -36 | 8 | -43 | -40 | -21 |
| Tax Paid ⓘ | 0 | 1 | 0 | 1 | 0 | 0 | 0 | -18 | -16 | -9 |
| Cash Flow From Investing Activity ⓘ | -2 | -4 | -4 | 0 | -4 | -5 | -16 | -16 | -24 | -16 |
| Capex | -2 | -6 | -5 | -3 | -6 | -6 | -18 | -21 | -29 | -18 |
| Net Investments | 0 | 0 | -1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Others ⓘ | 1 | 2 | 2 | 2 | 2 | 0 | 2 | 4 | 5 | 2 |
| Cash Flow From Financing Activityⓘ | -15 | -13 | 5 | -9 | -10 | 7 | -26 | -18 | 0 | -9 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 25 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -7 | -10 | -13 | -13 | -3 | 8 | 1 | 2 | 5 | -2 |
| Interest Paid ⓘ | 0 | 0 | -11 | -11 | -10 | -11 | -11 | -7 | -8 | -8 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -4 | -5 | -5 |
| Others ⓘ | -9 | -3 | 4 | 10 | 3 | 10 | -14 | -9 | 8 | 5 |
| Net Cash Flow ⓘ | -6 | 2 | 0 | -1 | -3 | 2 | 16 | 1 | -8 | -3 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 4.2 | 26.62 | 14.51 | 6.3 | -8.51 | 10.55 | 15.47 | 28.72 | 16.49 | 8.49 |
| ROCE (%) | 9.97 | 16.83 | 14.74 | 9.25 | -1.18 | 12.77 | 16.98 | 31.27 | 19.68 | 11.43 |
| Asset Turnover Ratio | 0.74 | 0.93 | 0.92 | 0.75 | 0.63 | 0.66 | 0.7 | 1.07 | 0.82 | 0.79 |
| PAT to CFO Conversion(x) | 5.5 | 1.27 | -0.13 | 0.89 | N/A | 0 | 2.11 | 0.55 | 0.37 | 0.88 | Working Capital Days |
| Receivable Days | 79 | 71 | 71 | 101 | 141 | 159 | 143 | 83 | 127 | 155 |
| Inventory Days | 106 | 82 | 76 | 84 | 102 | 97 | 89 | 55 | 67 | 67 |
| Payable Days | 317 | 267 | 210 | 196 | 202 | 227 | 165 | 87 | 131 | 138 |
Themis Medicare (TML) incorporated in 1969, is engaged in manufacturing of Active Pharmaceutical Ingredients (APIs) and Formulations. Erstwhile known as Themis Chemical the company is promoted by Mr. Shantibhai D. Patel. It is joint venture with Gedeon Richter, Hungary.
Headquartered in Mumbai, the company has four manufacturing facilities located at Vapi (Gujarat), Hyderabad (Andhra Pradesh), and Haridwar (Uttaranchal).
The company is backed by strong marketing workforce of 500 people with network of over 2000 stockists. The company has pan-India presence; it also has presence in 40 countries that include international markets namely Europe, Americas and Australasia.
Company has an in-house R&D facility that focuses on development of new chemical, new and efficient processes for production of API and intermediates, fermentation technology and New Drug Delivery Systems.
Themis Medicare is also engaged in supplying its research formulations to well known Pharmaceutical companies in India namely Alkem Lab, Fulford, Intas Pharmaceuticals, IPCA Lab., Cadila Healthcare, Aristo Pharma, Mankind Pharma, Shreya Lifesciences, Nicholas Piramal, Unichem Lab, etc.
Products
Active Pharmaceutical Ingredients- The Company is manufactures APIs that caters to therapeutic segment such as antituberculosis, antimalarials, cardiology, pain management, anti-infectives, haematinics, health and nutrition. Company manufactures products namely Simvastatin, Lovastatin, Propofol, Ethambutol, Di-methyl Isosorbide, Artesunate, Lumefenterine, Arteether are among others.
Formulations- The company also formulations that caters to therapeutic segment. It has produced products such as Themibutol, Tetracox, Tricox, Ticinex, Ticin are among others.
Milestones
1969- Themis Chemicals was incorporated in joint venture with GEDEON Richter, Hungary.
1971- Themis Chemicals became first company in India and second company in the world to manufacture Vitamin B12 by non-sterile fermentation process.
1976- Themis Chemicals became first company in India and second company in the world to manufacture Ethambutol Dihydrochloride.
1985- RIFAMPICIN was produced for first time in India by Themis Chemicals.
1990- Company developed and manufactured HEMOLOK.
1991-92 Besides Schering Plough of USA, company was only one to manufactures SISOMICIN. Company developed and manufactured ANABLOKTM – an anaesthetic.
1993- It was only private sector company to produce GENTAMICIN in India
1995- For the first time in the world the company produces FUMAGILLIN– a unique veterinary productThemis Chemicals is listed on the Bombay Stock Exchange.
1996- The company became first in India and third in the world to produce LOVASTATIN.
1997- Company received award from Ministry of Science and Technology’s Department of Scientific and Industrial Research (DSIR).
1998- Company developed Simvastatin for the first time in Asia.
1999- Company launched E MALTM – Alpha Beta Arteether and it also received award from Ministry of Science and Technology’s Department of Scientific and Industrial Research (DSIR) for the same.
2001- Company was rechristened as Themis Medicare
2002- The company for first time in India developed SEPGARDTM – a unique wound healing agent.
2003- For first time in the world, company developed CLEOFOLTM- a Lipid free Clear Propofol Injection. In the same year it also introduced the first COX-2 INJECTION in the world.
2004- Artemis Biotech was merged with Themis Medicare. The company forms its second joint venture with Gedeon Richter of Hungary to set up 100% export oriented unit under the name Richter Themis Medicare (INDIA). The same year the company commissions a new facility at Hyderabad.
2006- Company starts operations of its manufacturing unit located at Haridwar. Company develops and introduces Nimesulide Injection. Company launches THEMISEALTM- a stops bleeding gel and forays in European market. Company started cultivation of Artemisia annua and extraction of Artemisinin.
2007- For first time in the world, the company introduced Aceclofenac Injection.
2010 - Themis Medicare launched a combination of Lidocaine & Prilocaine in 'Spray' form under the brand name ""Lovelong""
2011 - Themis Medicare have introduced for the First Time in the Country a 'calcium' preparation with fruitygummies for paediatric use under the brand name "THEMIBEAR".
The Company have introduced for the First Time in the country a ""Multivitamin"" for Paediatric use under the brand name "THEMIBEAR"
2013 - Introduction of oil free Emal (Alpha beta arteether injection) in ampoules, and PFS (Pre-Filled Syringe)
Break through development of Diclofenac 75 mg / ml injection using patented technology and assigned exclusive marketing rights to Novartis India Limited under their flagship brand - Voveran 75 mg / ml Injection
Long term partnership signed with Novartis India Limited for exclusive marketing rights of Diclofenac TPM Gel (Voveran TPM Gel) for India
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
